JP2006517970A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517970A5
JP2006517970A5 JP2006503521A JP2006503521A JP2006517970A5 JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5 JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006503521 A JP2006503521 A JP 2006503521A JP 2006517970 A5 JP2006517970 A5 JP 2006517970A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
cancer
cancer therapeutic
antibody
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/004116 external-priority patent/WO2004074437A2/en
Publication of JP2006517970A publication Critical patent/JP2006517970A/ja
Publication of JP2006517970A5 publication Critical patent/JP2006517970A5/ja
Pending legal-status Critical Current

Links

JP2006503521A 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法 Pending JP2006517970A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44771403P 2003-02-14 2003-02-14
PCT/US2004/004116 WO2004074437A2 (en) 2003-02-14 2004-02-13 Compositions and methods for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2006517970A JP2006517970A (ja) 2006-08-03
JP2006517970A5 true JP2006517970A5 (https=) 2007-04-05

Family

ID=32908487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503521A Pending JP2006517970A (ja) 2003-02-14 2004-02-13 癌免疫療法のための組成物及び方法

Country Status (5)

Country Link
US (3) US8795672B2 (https=)
EP (1) EP1599572A4 (https=)
JP (1) JP2006517970A (https=)
CA (1) CA2516028C (https=)
WO (1) WO2004074437A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074437A2 (en) * 2003-02-14 2004-09-02 University Of Southern California Compositions and methods for cancer immunotherapy
AU2005302459A1 (en) * 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
GB0525535D0 (en) * 2005-12-15 2006-01-25 Cgt Corp Tumour treatment
US20090317407A1 (en) * 2006-05-02 2009-12-24 Lacelle Michael G Augmentation of immune response to cancer vaccine
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
EP2211903A4 (en) * 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
US11071754B2 (en) * 2013-03-11 2021-07-27 Case Western Reserve University Method of generating tumor-specific T cells
WO2014144666A2 (en) * 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
WO2015058148A1 (en) * 2013-10-17 2015-04-23 Children's Hospital Los Angeles Antibody dependent exosome therapy
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
CN109415431A (zh) 2016-04-20 2019-03-01 爱兰细胞技术公司 与k180二甲基化h1.0蛋白相关的组合物和方法
AU2017362730B2 (en) 2016-11-21 2021-04-08 Nant Holdings Ip, Llc Fractal combination therapy
CN115947859A (zh) * 2017-03-20 2023-04-11 癌症治疗实验室有限公司 用于在癌症疗法中靶向坏死的人源化抗核抗体
JP7252953B2 (ja) 2017-10-25 2023-04-05 エアラン セル テクノロジーズ， インコーポレイテッド Ｈ１．０ｋ１８０ｍｅ２抗体、その作製および使用の方法
KR102909650B1 (ko) 2018-03-13 2026-01-08 터스크 테라퓨틱스 리미티드 종양 특이적 세포 고갈에 대한 항-cd25
CN113613727A (zh) * 2019-01-11 2021-11-05 嘉立医疗科技(广州)有限公司 多特异性前趋化因子治疗蛋白（park）及其制备和使用方法
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
WO1991015515A1 (en) 1990-04-06 1991-10-17 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
US6356619B1 (en) * 2000-06-02 2002-03-12 General Electric Company Varying x-ray tube focal spot dimensions to normalize impact temperature
MXPA03006587A (es) * 2001-01-24 2003-09-22 Schering Corp Quimiocinas como adyuvantes de respuesta inmune.
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004074437A2 (en) 2003-02-14 2004-09-02 University Of Southern California Compositions and methods for cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2006517970A5 (https=)
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
DeVita et al. The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
EP3057991B1 (en) Chimeric antigen receptor t cell switches and uses thereof
Wu et al. Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy
ES2981745T3 (es) Agentes de señalización biespecíficos y usos de los mismos
Uricoli et al. Engineered cytokines for cancer and autoimmune disease immunotherapy
Mack et al. The next generation of antibody drug conjugates
KR20230147740A (ko) Pd-1/pd-l1 억제제
JP2016509582A5 (https=)
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
JP2017507936A5 (https=)
CA2516028A1 (en) Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
Quiles et al. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy
WO2006050172A3 (en) Combination cancer immunotherapy with co-stimulatory molecules
RU2017144606A (ru) Иммуноцитокины на основе il-15 и il-15rа домена sushi
JP2018510132A5 (https=)
JP2025072462A (ja) 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化
JP2012102122A5 (https=)
AR042977A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
KR20160022370A (ko) 면역요법을 위한 조성물 및 방법
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
JP2025527534A (ja) 抗－ヒト表皮成長因子受容体２（ｈｅｒ２）キメラ抗原受容体（ｃａｒ）を含むナチュラルキラー細胞を投与する方法
Hutchinson et al. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma